Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592930 | SCV000703008 | uncertain significance | not provided | 2016-10-24 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001867930 | SCV002154734 | uncertain significance | Nephronophthisis | 2022-09-27 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 498139). This variant has not been reported in the literature in individuals affected with NPHP3-related conditions. This variant is present in population databases (rs183049702, gnomAD 0.02%). This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 756 of the NPHP3 protein (p.Arg756Trp). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt NPHP3 protein function. |
Fulgent Genetics, |
RCV002483590 | SCV002787793 | uncertain significance | Renal-hepatic-pancreatic dysplasia 1; Nephronophthisis 3; NPHP3-related Meckel-like syndrome | 2021-12-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003243206 | SCV003965024 | uncertain significance | Inborn genetic diseases | 2023-05-05 | criteria provided, single submitter | clinical testing | The c.2266C>T (p.R756W) alteration is located in exon 16 (coding exon 16) of the NPHP3 gene. This alteration results from a C to T substitution at nucleotide position 2266, causing the arginine (R) at amino acid position 756 to be replaced by a tryptophan (W). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |